TECHNOLOGY
NeoVac provides proprietary, clinically tested, fully biodegradable, tissue-specific LNPs, powered by its extensive lipid library that offers first-in-class and best-in-class opportunities
Lipid diversity ~ library of unlimited unique ionizable lipids
Patented lipids with superior safety and tuneable immunogenicity and ability to go after indications not previously suitable for LNPs
Fully Biodegradable and thermostable by design
Target specialised extrahepatic delivery to different organs and cell types.
Highly skilled team consisting of former Pfizer, BioNtech, Genevant, AstraZeneca, and Nitto Denko experts in RNA and LNP technologies
Controlled Immune Response
Tissue Targeting Specificity
Route of Administration
High Immunogenicity
(for vaccines)
Low Immunogenicity
(for therapies)
Very high
(for cell specific
therapies)
High
(for tissue specific
therapies)
Medium
(for organ specific
therapies)
Low
(for vaccines)
Systemic IM, ID, SC injection
(not targeting specific tissues) e.g. vaccines
Systemic injection IM, ID, SC
(targeting specific tissues) e.g. bowels, lungs
Regional inhaled or topical administration
(targeting specific tissues) e.g. CF
Local injection
into specific tissues